Addressing the persistent challenges in treating metastatic neuroendocrine tumors (NETs) demands ongoing refinement and innovation in therapeutic strategies. This study investigates the potential advantages of combining metronomic temozolomide (mTMZ) with bevacizumab for patients diagnosed with metastatic NETs, particularly focusing on those with a Ki-67 index under 55%. Data from 30 patients were analyzed, using key performance indicators such as progression-free survival (PFS), overall survival (OS), and response rates to therapy, to gauge the treatment’s efficacy. The results were encouraging: the median PFS recorded was 16.3 months, and the OS was 25.9 months. The disease control rate (DCR) reached an impressive 86.7%, and the objective response rate (ORR) stood at 63.3%. The treatment regimen was well-tolerated, with no reported instances of grade 4 toxicities. Such a safety profile indicates that this regimen may be particularly advantageous for older, fragile patients who might struggle with conventional dosage levels. These initial findings suggest that the mTMZ and bevacizumab combination could potentially rival the conventional temozolomide–capecitabine therapy in managing metastatic NETs. We aimed to meticulously assess the efficacy of the mTMZ and bevacizumab combination in treating metastatic NETs. Given the initial promising results, a more conclusive understanding of its efficacy will require further research through larger, multicenter prospective clinical trials.
针对转移性神经内分泌肿瘤（NETs）治疗中持续存在的挑战，需要不断优化和创新治疗策略。本研究探讨了节拍式替莫唑胺（mTMZ）联合贝伐珠单抗对于诊断为转移性NETs患者的潜在优势，尤其关注Ki-67指数低于55%的患者。通过分析30例患者的数据，采用无进展生存期（PFS）、总生存期（OS）和治疗反应率等关键绩效指标来评估该疗法的疗效。结果令人鼓舞：中位PFS为16.3个月，OS为25.9个月。疾病控制率（DCR）达到86.7%，客观缓解率（ORR）为63.3%。该治疗方案耐受性良好，未报告4级毒性事件。这种安全性特征表明，该方案可能特别适用于那些难以耐受常规剂量水平的老年体弱患者。这些初步发现提示，在治疗转移性NETs方面，mTMZ联合贝伐珠单抗方案可能与传统替莫唑胺-卡培他滨疗法相媲美。我们旨在细致评估mTMZ联合贝伐珠单抗治疗转移性NETs的疗效。鉴于初步结果良好，要对其疗效获得更确切的结论，需要通过更大规模、多中心的前瞻性临床试验进行进一步研究。
肿瘤(癌症)患者之家